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Simple Summary: The crosstalk between multiple myeloma and immune cells within the bone
marrow niche has been identified as an emerging hallmark of this hematological disease. As our
knowledge on this interplay increases, it becomes more evident that successful treatment approaches
need to boost the body’s natural defenses through immunotherapy. The present review will focus on
the mechanisms by which myeloma cancer cells turn immune populations into their “partners in
crime”. Additionally, we will provide an overview of currently ongoing pre-clinical studies targeting
the bone marrow immune microenvironment.
Abstract: Multiple myeloma (MM) is one of the most prevalent hematological cancers worldwide,
characterized by the clonal expansion of neoplastic plasma cells in the bone marrow (BM). A com-
bination of factors is implicated in disease progression, including BM immune microenvironment
changes. Increasing evidence suggests that the disruption of immunological processes responsible for
myeloma control ultimately leads to the escape from immune surveillance and resistance to immune
effector function, resulting in an active form of myeloma. In fact, one of the hallmarks of MM is
the development of a permissive BM milieu that provides a growth advantage to the malignant
cells. Consequently, a better understanding of how myeloma cells interact with the BM niche com-
partments and disrupt the immune homeostasis is of utmost importance to develop more effective
treatments. This review focuses on the most up-to-date knowledge regarding microenvironment-
related mechanisms behind MM immune evasion and suppression, as well as promising molecules
that are currently under pre-clinical tests targeting immune populations.
Keywords: multiple myeloma; tumor microenvironment; cancer immunity; immunotherapy
1. Introduction
Multiple myeloma (MM) is the second most frequent hematological cancer worldwide
with a global incidence of 159,985 new cases in 2018 [1]. MM is an aggressive malig-
nancy characterized by the clonal expansion of terminally differentiated B cells in the
bone marrow (BM) and clinically defined by increased BM plasmacytosis, serum and/or
urine monoclonal immunoglobulin, secretion of free light chains, hypercalcemia, renal
insufficiency, anemia, and bone pain due to osteolytic disease [2,3]. This disease is preceded
by an asymptomatic premalignant condition termed monoclonal gammopathy of uncertain
significance (MGUS), and in some patients, it is possible to distinguish an intermediate
stage called smoldering MM (SMM) [4,5].
The MM BM niche is a heterogeneous system where the crosstalk between neoplastic
plasma cells and immune populations, from both myeloid and lymphoid lineage, plays a
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critical role in myelomagenesis and maintenance. Indeed, myeloma cells display a wide
variety of mechanisms that induce a permissive microenvironment, allowing immune
evasion and favoring its own proliferation, survival, migration, and drug resistance [6,7].
Consequently, the search for novel and more effective drugs that kill tumor cells and/or
boost the immune system has increased in the last years. Yet, despite substantial progress in
classification, staging, and treatment, the majority of MM patients still have only a median
of four to five years of survival after starting treatment [8]. Many of these patients relapse
due to the presence of residual malignant cells that may be undetectable by currently
available monitoring techniques as next generation sequencing or flow cytometry [9]. A
major scientific and clinical challenge in this disease is finding a balance between myeloma
cell killing efficacy and toxicity for patients. Therefore, considering the role of immunity
in MM, a deeper understanding of the interaction between neoplastic plasma cells and
the BM immunome is of utmost importance for the development of more effective and
safe treatments.
Of note, there are other non-immune populations, such as mesenchymal stromal cells
or osteoclasts/osteoblasts, as well as metabolic pathways that are deregulated, leading
to drug resistance and myeloma’s escape from immune surveillance [10–12]. Notwith-
standing, this review exclusively focuses on the current state of the art regarding the BM
immune microenvironment.
2. Myeloma Immune Microenvironment: From Surveillance to Immune Escape—The
Concept of Immunoediting
MM is an excellent cancer immunoediting example in which a premalignant equilib-
rium phase—MGUS—anticipates the escape phase of active disease [13,14]. The precursor
stages, as MGUS and SMM, already harbor malignant clones characterized by genomic
changes (e.g., IgH translocations or hyperdiploidy) [15,16]. MM progression is a process far
more complex than the first alterations occurring in these neoplastic cells. This evolution is
driven by subsequent acquisition of other genetic transformations, including MYC translo-
cations, 1q gains, or TP53 mutations [17,18]. Presently, it is evident that composition and
function of the immune components in the BM myeloma niche relate with MM progression
and aggressiveness [19–22].
A summary of the different phases of MM development and their crosstalk with the
immune microenvironment are shown in Figure 1. Cell populations relevant in the MM
immune niche will be addressed subsequently.
2.1. Myeloid-Derived Suppressor Cells
In the last years, myeloid-derived suppressor cells (MDSCs), a heterogeneous pop-
ulation of immature myeloid cells, have emerged as negative regulators in infection,
autoimmune diseases, sepsis, and cancer [23–25]. On the basis of their morphological and
phenotypic properties, these cells can be further divided into polymorphonuclear MDSCs
(PMN-MDSCs) and monocytic MDSCs (M-MDSCs) [26]. Functionally, it is known that
PMN-MDSCs are more suppressive than M-MDSCs [27].
The role of MDSCs as MM-promoters in the BM microenvironment is just starting to
be unraveled. MDSCs accumulate in the BM of both patients and MM-bearing mice [28–32]
and their levels correlate with the disease stage and prognosis [30,33]. Interestingly, a study
from Binsfeld et al. showed that reduced levels of PMN-MDSCs were associated with
less formation of blood vessels, and M-MDSCs were identified as osteoclast precursors,
favoring disease progression [27]. These results suggest that MDSCs sub-populations act in
different ways in the BM milieu of MM. Thus, we could hypothesize that targeting MDSCs
in general could not only improve anti-MM immunity, but also modulate angiogenesis and
osteolytic bone disease in MM patients.
The S100A9 knock-out (KO) murine model represents an excellent example to study
the effect of MDSCs depletion, since they are deficient in their ability to accumulate
MDSCs [34]. Therefore, several pre-clinical studies have used this model to study the
involvement of these cells in the promotion of an impaired BM immunity in MM. For
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instance, Ramachandran and colleagues showed that upon tumor establishment, MDSCs
accumulate in the BM of MM-bearing mice, and this was accompanied by the inhibition
of anti-tumor cytotoxicity and a decrease in the presence of Th1 CD4+T cells. By using
the S100A9 KO murine model, they found a reduced accumulation of MDSCs and a re-
establishment of anti-tumor immunity, decelerating MM progression [28]. Additionally,
Görgün and colleagues showed that neoplastic plasma cells and MDSCs interact in a
“win-win” mode within the BM niche. While myeloma cells promote MDSCs development
and survival, MDSCs create a protective environment by inducing NK T and CD8+T
cells anergy. This effect is mediated by soluble factors produced by MDSCs, such as
inducible nitric oxide synthase (iNOS), arginase (ARG1), reactive oxygen species (ROS), and
immunosuppressive cytokines, including IL-6 and IL-10. This study also demonstrated that
the expression of these cytokines was abrogated using currently available therapies, such
as bortezomib and lenalidomide. However, the number or functional immunosuppression
of MDSCs was not abolished by in vitro exposure to these agents [30]. Conversely, in
another study by Wang et al., treatment with these same agents resulted in a decreased
frequency of MDSCs [33]. The data on the effect of currently available therapies tackling
MM MDSCs are still inconsistent and need further study. Nonetheless, Ramachandran
and colleagues showed that these suppressive effects can be reduced by decreasing the
number of MDSCs, leading to a significant delay in myeloma proliferation and improved
response to chemotherapy (e.g., doxorubicin) [35]. Thus, these results suggest that one
effective way to overcome chemoresistance in MM might be through the combination of
currently available drugs with MDSCs-depleting agents. Also aligned with this hypothesis,
Wang et al. used the murine 5T33MM model to demonstrate an indirect mechanism
supporting MM progression, in which MDSCs uptake BMSC-derived exosomes in the BM
microenvironment. This phenomenon induces MDSCs expansion in vitro and enhances
the immunosuppression on T cells through the secretion of nitric oxide. Specifically, these
exosomes can improve MDSCs survival, not only by activating STAT3 and STAT1 pathways
but also by increasing anti-apoptotic proteins (e.g., Bcl-xL and Mcl-1) [36].
Taken together, these studies demonstrate that MDSCs work in favor of myeloma
plasma cells and are able to regulate the efficacy of currently used chemotherapies and
novel immunotherapeutic agents [37,38]. Therefore, MDSCs-depleting/targeted drug
strategies may relieve immunosuppression found in the BM MM niche and subsequently
augment the anti-tumor effect of concomitant therapies for MM patients.
2.2. Macrophages
Macrophages are professional phagocytic cells that play a crucial role in pathogen
elimination as well as in tissue repair. They are classified under two major phenotypes:
M1 and M2. In a tumor bed, M1 pro-inflammatory macrophages act as potent anti-tumor
effectors by antagonizing the suppressive activities of pro-tumoral cells, whereas anti-
inflammatory M2 macrophages are involved in anti-tumor suppression [39,40]. During
neoplastic progression, M1 macrophages may gradually lose their anti-tumor properties
and acquire a M2-like phenotype, also known as Tumor-Associated Macrophages (TAMs).
The role of TAMs in cancer development have been extensively studied, showing their
potential value not only as diagnostic and prognostic biomarkers, but also as therapeutic
targets [41,42].
In MM, several studies reported a correlation between a higher CD163+ macrophages
infiltration of the BM and a more aggressive disease, shorter patient survival, and response
to treatment [43–45]. In addition, a recent publication revealed that higher levels of
CD68+/CCR2+ macrophages in patients treated with bortezomib were correlated with
a worse outcome, suggesting that pro-inflammatory macrophages represent a potential
predictive biomarker for MM resistance to bortezomib therapy [46].

































Figure 1. The 3E’s of immunoediting in the multiple myeloma (MM) bone marrow (BM) 
microenvironment. Immune cells can either eliminate cancer cells or facilitate escape from 
immune surveillance according to environmental cues. When neoplastic plasma cells start to 
arise, they can be recognized as strange and be eliminated by immune cells (Elimination 
Phase—“FOES”). However, cells can reach an equilibrium phase that involves a continuous 
eradication of myeloma cells. At the same time there is a Darwin selection of the most 
resistant clones and a decrease of immunogenic tumor cells. This stage is probably the 
longest phase and may occur over a period of several years, as it happens in monoclonal 
gammopathy of uncertain significance (MGUS) and low risk smoldering MM (SMM) 
patients. Afterwards, this novel population of myeloma clones that can model immunity, will 
grow and expand (Escape Phase—“FRIENDS”). pDC: plasmacytoid dendritic cell; mDC: 
myeloid dendritic cell, gd: gamma-delta T cells; Bregs: regulatory B cells; Tregs: regulatory T 
cells; M-MDSCs: monocytic myeloid-derived suppressor cells; PMN-MDSCs: 
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Figure 1. The 3E’s of immunoediting in the multiple myeloma (MM) bone marrow (BM) microenvironment. Immune cells
can either eliminate cancer cells or facilitate escape from immune surveillance according to environmental cues. When
neoplastic plasma cells start to arise, they can be recognized as strange and be eliminated by immune cells (Elimination
Phase—“FOES”). However, cells can reach a equilibrium phase that involves a continuous eradic ti n of myeloma cells. At
the same time there is a Darwin selection of the most resistant clones and a decrease of immunogenic tumor cells. This stage
is probably the longest phase and may occur over a period of several years, as it happens in monoclonal gammopathy of
uncertain significance (MGUS) and low risk smoldering MM (SMM) patients. Afterwards, this novel population of myeloma
clones that can model immunity, will grow and expand (Escape Phase—“FRIENDS”). pDC: plasmacytoid dendritic cell;
mDC: myeloid dendritic cell, gd: gamma-delta T cells; Bregs: regulatory B cells; Tregs: regulatory T cells; M-MDSCs:
monocytic myeloid-derived suppressor cells; PMN-MDSCs: polymorphonuclear MDSCs. Adapted from Dunn et al.,
2004 [13].
Currently explored MM therapeutic strategies involve macrophage recruitment in-
hibition to the tumor micro nvironment or macrophage depl tion by targeted apoptosis
induction. F r instance, a repo t by Beider et al. showed that myeloma-derived CXCL12
could attract and recruit onocy es Of note, this migration could be further enhanced
either by BM stromal cells alone, that also secrete CXCL12, or through their reciprocal
interaction with neoplastic plasma cells, leading to monocytes’ differentiation towards a
M2 phenotype. Moreover, researchers found that the CXCR4/CXCL12 axis was critically
involved in these migratory signals, since the neutralization of CXCR4 abrogated monocyte
recruitment. Finally, this immunosuppressive phenotype was shown to suppress T cell
responses, promote the formation of novel blood vessels, support myeloma cell growth
and chemoresistance [47]. Overall, this study supports that the presence of macrophages
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with an anti-inflammatory phenotype in the BM microenvironment may negatively affect
prognosis and/or treatment response.
As macrophages keep an inherent anti-tumor potential in the BM niche, another
promising approach involves macrophage reprograming. Injection of xenograft tumor
mouse models with a combination of GM-CSF (Pro-M1) and 4-IPP (M2 inhibitor) was
shown to induce reprogramming towards an M1 profile, at both gene and protein expres-
sion levels, as well as remarkable tumoricidal effects [48].
Altogether, these results demonstrate that macrophages are critical actors in the
settlement and the progression of MM. Moreover, macrophages can be “manipulated” by
myeloma cells to serve the cause of the tumor. Notwithstanding, several macrophages-
reprogramming therapies are currently under study in order to recover them as partners
instead of enemies.
2.3. Dendritic Cells
Dendritic cells (DCs), as professional antigen-presenting cells, act as a link between
innate and adaptive immunity [49]. DCs can be further divided into two subclasses on
the basis of their morphology and function: myeloid DCs (mDCs) and plasmacytoid DCs
(pDCs) [50]. mDCs secrete IL-12 and play an important role in enhancing adaptive immune
responses [51]. Conversely, pDCs are specialized IFN-producing cells, with an important
role in the activation of Toll-like receptors (TLRs) such as TLR7 and TLR9 upon viral
infections [52].
Although there is not a complete agreement in the literature regarding DCs frequency,
phenotype, and function in MM patients’ BM versus healthy BM, it is assumed that MM
patients’ BM DCs are functionally defective. Indeed, several research groups already
demonstrated that some immunological properties of DCs are compromised during myelo-
magenesis, diminishing effective anti-tumor immune responses and leading to myeloma
escape. This includes a lack of expression of HLA-DR, CD40, CD80, and CD86 molecules
and defective antigen presentation compared to healthy samples [53]. Furthermore, some
activation markers have been reported to be associated with the defective differentiation of
monocyte-derived DCs (Mo-DCs) found in the peripheral blood (PB) of MM patients. For
instance, in a study performed by Wang et al., higher production of IL-6 was found, as well
as increased levels of p38 and STAT3, with the inhibition with Raf/MEK/ERK signaling
pathways in MM-derived progenitor cells compared to healthy donors. Furthermore,
treating these cells with an anti-IL-6 alone or with a p38 inhibitor not only increased the
number of circulating DC but also restored their phenotype and functionality [54]. In
another study from Kukreja et al., the crosstalk between DCs and neoplastic plasma cells
was reported as supporting myeloma’s proliferation by RANK-RANK ligand and APRIL
interactions, which can be abrogated through its blockade. In this regard, direct targeting
of DCs may also be a fruitful treatment for MM. As such, in vitro blockade of RANKL and
APRIL pathways have shown to inhibit DCs-mediated myeloma proliferation [55]. More
recently, Shinde and colleagues demonstrated that Mo-DCs were functionally defective
due to lower expression of IL12p70 and higher levels of IL-10 production in myeloma
patients, leading to impaired T helper (Th) 1 response. Additionally, these cells displayed
compromised CCR7-dependent migration to lymph nodes, which could be attributed to
the higher production of IL-6 and activation of the p38 MAPK pathway found in samples
from MM patients compared to healthy subjects [56]. Altogether, these data are particularly
relevant because Mo-DCs are being considered to be used as vaccines, and it raises the
question of whether they are the ideal vehicles for antigen delivery in MM treatment.
Furthermore, immature DCs were found to contribute to myeloma-induced osteol-
ysis, and this phenomenon is believed to be induced by IL-17A, which was found to be
significantly increased in MM patients [57]. Thus, targeting the IL-17 pathway might be a
strategy to avoid osteoclagenesis, which is typical of this disease.
Under homeostatic conditions, stimulated pDCs are known to have a strong antigen-
presenting potential. However, researchers already showed that in the MM setting these
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pDCs are defective in antigen presentation, leading to weak stimulation of T-cell prolif-
eration [58]. For instance, in a study conducted by Chauhan et al., they found that there
was an increase in the number of pDCs in the BM of myeloma patients. In addition, these
cells interact directly with neoplastic plasma cells and produce soluble factors capable
of promoting tumor growth and conferring drug resistance, including IL-3, IL-6, IL-10,
IL-8, IL-15, VEGF, MCP-1, or CXCL12, which may allow pDCs survival, migration, and
homing to BM. Importantly, by blocking either IL-3 or CXCL12, myeloma cell growth
was markedly abrogated. In that study, although pDCs were resistant to anti-myeloma
therapies, including bortezomib, lenalidomide, and dexamethasone, targeting TLRs with
CpG oligodeoxynucleotides restored pDCs immune function and aborted pDCs-induced
myeloma cell growth [59]. These evidences suggest that targeting pDCs-MM interaction
might be an interesting therapeutic strategy to overcome drug resistance in MM. Similar to
these findings, Ratta et al. deeply characterized circulating DCs isolated from MM patients,
in which they found that the total amount of both mDCs and pDCs was significantly less in
myeloma patients compared to healthy individuals. Interestingly, IL-6 production inhibited
the growth of CD34+DC progenitors and switched their commitment into monocytic cells
with phagocytic activity, abrogating antigen presentation ability. Still, blocking IL-6 using
neutralizing antibodies did not completely revert this inhibitory effect [60], indicating that
other soluble factors may contribute to DCs dysfunction, such as IL-10 or TGF-β [53,61,62].
Overall, these results suggest that one of the mechanisms by which neoplastic plasma cells
evade immunity is only partially mediated by IL-6 production.
Conversely, in another study, Leone et al. found that both mDCs and pDCs accumulate
in the BM of patients during MGUS-to-MM progression and these numbers correlate
positively with the proportion of plasma cells in both MGUS and MM patients, indicating
that DCs accumulation is proportional to tumor burden. Importantly, they seem to play
a dual role in the MM BM microenvironment: on the one hand, DCs activate cytotoxic
CD8+T cells against tumor cells through engulfment of apoptotic plasma cells and, on
the other hand, DCs protect myeloma cells against CD8+T cell killing by downregulation
of proteasome subunits in a contact-dependent manner involving the CD28-CD86/CD80
axis [63,64]. Thus, it is imperative to take this mechanism into account when designing
novel immunotherapy strategies that aim to improve immune surveillance in the early
stages of disease and/or break down immune defenses in active MM. For instance, blocking
CD28 interactions using a CTLA-4 monoclonal antibody (mAb) could prevent the immune
escape of myeloma cells and make them more susceptible to CD8+ T cells.
More recently, Ray et al. performed RNA sequencing analysis, where they identified
the main pDCs-MM contact-dependent alterations responsible for tumor proliferation and
immunosuppression. They found that the co-culture of pDCs and myeloma cells leads
to an increase in the expression of CD73, TLR7/9, HDAC6, PD-L1, or IL3Rα/CD123 and
reduces CASP3, BAK1, ADAM33, and BAD gene expression in tumor cells. Notably, by
blocking CD73 it was possible to reactivate CD8+ T cell activity against myeloma cells.
Moreover, the combination of an anti-CD73 with a TLR7 agonist increased even more the
cytotoxic activity of lymphocytes. As such, these results bring novel therapeutic targets
that might be used in order to improve MM therapy [65].
Altogether, these findings explain how the crosstalk between myeloma cells and DCs,
either through cell-to-cell contact or soluble factors, impairs an effective anti-tumor immune
response in the BM microenvironment, turning DCs into faithful allies of myeloma plasma
cells. The understanding of the molecular interactions between myeloma and DCs may be
turned into knowledge applied to the design of treatment approaches to MM.
2.4. T and NK Cells
T- and NK-cell immunity plays a pivotal role in the interplay with MM plasma cells
within the BM milieu. Defects in T cell distribution and function have been documented in
MM, including the decrease of CD8+ and CD4+T cell frequency, abnormal Th1/Th2 ratio
and impaired T cell responses [66]. Even in the precursor stages of plasma cell dyscrasia,
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evidence of T-cell dysfunction has been reported. For instance, MGUS patients showed
increased levels of T cell exhaustion and a higher presence of regulatory T cells (Tregs) [67].
In SMM patients, there is a reduced expression of activation markers compared with
healthy controls, such as CD25, CD28, and CD54 [68]. These phenotypic aberrations at
early stages worsen throughout the disease course [69]. Although anti-myeloma effector
responses seem to be efficiently primed, they subsequently fail as myeloma cells are able to
circumvent T-cell effector functions through an array of mechanisms, such as defects in
cytokine secretion, loss of proliferative capacity, impaired cytotoxicity, altered activity of
transcription factors such as T-bet or the expression of immune checkpoint inhibitors (ICIs),
including PD-1, CTLA-4, or TIGIT [70]. Immune checkpoint signaling is a key pathway
to regulate the balance between activation and tolerance that, if altered, ultimately leads
to the escape from immune surveillance. In MM patients, PD-1 is upregulated on T cells
after activation [71] and direct interaction with its ligand (PD-L1) expressed in myeloma
cells inhibits the T cell function by impairing proliferation and cytokine secretion [72]. In
animal models, it was shown that the expression of exhaustion and senescence markers
by T cells after autologous transplant is associated with clinical relapse, and treatment
with anti-PD-1 ex vivo reinvigorated them to produce effector cytokines [73]. A higher
number of PD-1+ T cells was detected in BM from relapsed/refractory (RR) MM patients
than in newly diagnosed or partial/complete remission MM patients, and were associated
with higher tumor burden and worst prognosis [74]. As PD-1 expression in T cells and
PD-L1 in MM cells contribute to relapse and drug resistance mechanisms, immune-based
therapeutic strategies that target checkpoint signaling with anti-PD-1 mAb could inhibit
tumor cell growth and restore immune function [75]. Another co-inhibitory receptor, TIGIT
was found to be expressed more frequently in CD8+T cells from MM patients than other
ICIs, and those effector cells displayed limited cytokine responses. In Vk*MYC TIGIT-null
mice, myeloma growth was delayed, and in wild type mice, tumor burden was reduced
with anti-TIGIT treatment [76]. In a murine model of MM relapse after stem cell transplant,
mice showed effector CD8+T cells with exhausted features, namely high TIGIT expression
and low CD226 expression, and the anti-TIGIT treatment was able to improve disease
control rates [21]. Nevertheless, a dysregulated BM immune microenvironment, with
dysfunction of cytotoxic CD8+T cells or decreased levels of stem-like/resident memory T
cells can lead to this type of therapeutic failure, compromising the efficacy of ICIs [77].
Immunomodulatory drugs currently used in MM treatment have demonstrated the
ability to increase T-cell anti-tumor activity by promoting apoptosis and downregulating
cytokine production [78]. As previously mentioned, within the MM BM niche, Th cells
are also dysfunctional. Impaired proliferation of CD4+T cells, alterations in the balance
between Th1 and Th2, with reduced Th1 cytokine production, overexpression of Th2
cytokines and expansion of pro-inflammatory Th17 cells, are some examples of how
myeloma plasma cells contribute to immune response suppression and escape from T-cell
surveillance [79]. Tregs, which can modulate overall immune responses against tumor
cells, also have an important role in immune suppression and evasion of myeloma plasma
cells [80]. Tregs inhibit the function of Th1 and Th17 cells, macrophages and DCs by direct
cellular interaction or by secreting suppressive cytokines, such as IL-10 or TGF-β [81].
The frequency of Tregs in the BM microenvironment has been shown to be increased in
MGUS patients that progress to MM, contributing to the early establishment of MM-related
immunosuppression [82]. Furthermore, the expansion of Tregs has a negative impact
on survival, which may hint at a potential therapeutic target [83]. Immunomodulatory
treatments, such as lenalidomide and pomalidomide exert an anti-MM activity by inhibiting
the proliferation and function of Tregs [84]. Similar to other immunosuppressive cells, such
as MDSCs or Bregs, Tregs express high levels of CD38 and can be directly targeted with
anti-CD38 antibodies to regulate the immune compartment and restore anti-MM T cell
responses in the BM [85]. The therapeutic implications of Tregs are numerous, including in
the development of vaccination strategies, as shown in a study in early-stage myeloma,
where immune response failure was associated with the increase in Tregs frequency [86].
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A small fraction of T cells, γδ T cells, were shown to have both adaptive and innate
anti-myeloma effector functions [87]. γδ T cells produce IFN-γ and exhibit cytotoxic
activity against MM cells after in vitro and in vivo activation with bisphosphonates and
IL-2 [88,89]. Bisphosphonates, including pamidronate and zolendronic acid used in MM
treatment, also enhance signaling through the receptor NKG2D, present not only on γδ T
cells but also in CD8+T cells and NK cells, following engagement with the ligand major
histocompatibility complex class-I related chain molecule A (MICA). MICA expression
on the surface of plasma cells correlates inversely with disease stage, being higher in
MGUS than in MM patients [90]. The shedding of MICA from myeloma cells leads to its
increase in the PB, subsequently triggering a downmodulation of NKG2D, which suggests a
possible immune escape process [90]. Though the use of γδ T cells as promising approaches
for immunotherapy in MM could be hampered by the need to previously expand their
number, the synergy with NK cells could be explored, as these cells seem to have similar
cytotoxic mechanisms.
NK cells are key innate immune players with direct cytotoxic activity and antibody
dependent cellular cytotoxicity (ADCC), triggered upon the recognition of ligands on
MM cells by activating receptors such as NKG2D, CD16, 2B4, NKp80 or DNAM-1 [91,92],
regulated by major histocompatibility complex class I (MHC-I)-binding inhibitory receptors,
such as killer cell Ig-like receptors (KIR) or CD94/NKG2A [93]. Contrary to CD8+T cells,
NK cells respond to germline-markers of oncogenic transformation that are present on
the surface of neoplastic plasma cells and not neoantigens presented by MHC-I, which is
an advantageous characteristic in a low neoantigen presentation tumor, such as MM [94].
Myeloma cells can evade NK cell activity by maintaining human leukocyte antigen (HLA)
expression [95] and by shedding MICA, leading to the downregulation or blocking of the
NKG2D receptor on NK cells [96]. Activation of Tregs by MM cells has also been implicated
in the inhibition of normal cytotoxic activity of NK cells [97]. Decrease in surface receptors
as NKG2D or natural cytotoxicity receptors (NCRs) in BM NK cells, DNAM-1 in PB NK
cells, and 2B4 in both PB and BM NK cells might contribute to the reduced functionality
observed in MM patients [92,98]. NK cells from myeloma patients are usually dysfunctional
compared to normal individuals and even to MGUS patients [99], and those with lower
NK cytotoxicity present worse disease-free survival [100]. Alterations in the distribution
of NK cell subset in MGUS and MM patients have also been detected, although there
are conflicting results in this regard, possibly due to differences in the methodologies
used [101–103]. Consequently, understanding the quantitative and functional alterations in
NK cells of MM patients is increasingly relevant as new NK cell-based immunotherapies
are being developed.
Overall, given all the strategies that myeloma cells use to escape lymphocytic surveil-
lance in the BM niche, the development and optimization of efficient T and NK cell therapies
are critically needed to improve outcomes in MM patients.
2.5. Regulatory B Cells
The role of B cell subsets in the MM BM microenvironment is still poorly described,
however regulatory B cells (Bregs) have attracted attention as emerging prominent players
in the initial stages of MM progression [104,105]. Bregs produce high amounts of IL-10 and
TGF-β and can transform naive Th cells into CD4+CD25+FoxP3+ Tregs in an IL-10/TGF-β-
dependent manner [106]. Generally, Bregs are described to maintain immune tolerance,
suppress autoimmune and inflammatory responses as well as to suppress immune response
during cancer progression.
Neoplastic cells may attract naive B cells into the tumor microenvironment through
chemoattractants and promote their differentiation into Bregs either directly, by releasing
soluble factors or through cell contact, or indirectly, by recruiting other immune cells, such
as IL-21-producing T cells, which in turn induce the local generation of microenvironment
suppressive Bregs. In addition, this population may inhibit the ability of CD4+ and CD8+T
cells to eliminate tumors [107,108], by inhibiting NK cell responses [109], causing Tregs
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proliferation [110,111], promoting the activity of TAMs and MDSCs, and directly promoting
tumorigenesis and angiogenesis [112].
The work from Zhang and colleagues demonstrated that the frequency of Bregs in the
BM of MM patients was significantly greater than in the PB, showing preferential accumu-
lation of Bregs in the BM niche. Furthermore, they showed the Bregs’ dependency on MM
cells for survival, through the depletion of CD138+ MM cells from the BM mononuclear cell
culture with elotuzumab causing Bregs cells’ apoptosis. MM-derived BM Bregs were more
immunosuppressive than their PB counterparts and were able to suppress anti-MM cell
ADCC by NK cells [104], supporting Bregs as a novel cellular target of future therapeutics.
In another study, Tai et al. have shown that Bregs highly express TACI compared with
naive B cells in MM patients. In vitro studies have shown that APRIL is able to increase the
frequency of BM Bregs and enhance IL-10 production leading to MM cells survival [113].
Moreover, the work from Zou and colleagues has shown an increase of Bregs in samples
from MM patients and bortezomib was able to eliminate Bregs [105]. Despite the evidenced
involvement of Bregs in MM, there have not been any in vivo studies published so far.
This knowledge has been integrated to develop immunotherapies against MM. Table 1
describes novel and encouraging immunotherapeutic approaches against BM immunome
in pre-clinical tests using MM mouse models. It should be noted that some aspects of
immune deregulation in MM may be related with autoimmunity and response to infections.
Indeed, several research groups have shown that sporadic MGUS and MM cases start by
chronic antigen stimulation [114–116].
Table 1. In vivo pre-clinical tests showing promising molecules against multiple myeloma (MM) bone marrow (BM) milieu
to overcome immunosuppression.
Molecular
Target In Vivo Pre-Clinical Studies Reference
IL-18 in MDSCs
Long-term blockade of IL-18 delayed
MM progression. Additionally, the
combination of IL-18 mAb+Bortezomib
significantly prolonged survival in MM
models originally established as
Bortezomib resistant.
Nakamura et al., 2018 [117]
piRNA-823
Silencing piRNA-823 in MM reduced the
stemness of myeloma stem cells
maintained by PMN-MDSCs, decreased
tumour burden and angiogenesis in vivo.
Ai et al., 2019 [118]
DCs vaccination + Lenalidomide +
anti-PD-1 mAb
This triple combination synergistically
induced a stronger anti-tumour immune
response by inhibiting MM growth in a
murine model.
Vo et al., 2018 [119]
TRL9 agonist C792
C792 recovers pDCs ability to stimulate T
cells and inhibits myeloma cell growth.
Importantly, this cytotoxic activity
enhances bortezomib, lenalidomide,
SAHA or melphalan.
Ray et al., 2014 [120]
Clodronate-liposomes
Depletion of CD169+ bone
marrow–resident macrophages in vivo
abrogates myeloma growth.
Opperman et al., 2019 [121]
CD40 mAb + CpG (TLR9)
Macrophage-activating immunotherapy
using CD40 plus CpG promoted
anti-tumor effect in a RR MM murine
model. This effect was increased when
Tpl2 kinase was also inhibited showing
an increase in both progression-free
survival and overall survival.
Jensen et al., 2015 [122]
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Table 1. Cont.
Molecular
Target In Vivo Pre-Clinical Studies Reference
Anti-PD-1 mAb
Treatment with anti-PD-1 ex vivo
reinvigorated T cells that expressed
exhausted and senescence markers to
produce effector cytokines.
Chung et al., 2016 [73]
Anti-TIGIT mAb expressed in T cells
In Vk*MYC TIGIT-null mice, myeloma
growth was delayed and in wild type
mice tumor burden was reduced with
anti-TIGIT treatment.
Guillerey et al., 2018 [76]
CS1-NKG2D bi-specific antibody in
NK cells
Anti-TIGIT treatment was able to
improve disease control rates in a murine
model of MM relapse after stem
cell transplant.
Prolonged survival in a humanized
MM model.
Minnie et al., 2018 [21]
Chang et al., 2018 [123]
3. Conclusions
The present review considered the role of the BM immune microenvironment during
MM progression when, undeniably, immune cells become myeloma’s best friends. As
previously described, this deregulation happens through several mechanisms, by which
MM cells use both myeloid and lymphoid populations to their advantage. Although several
gaps in the knowledge of how myeloma relates to immune cells and vice-versa subsist, it is
evident that, in order to recover the immune system, we need to break up this friendship
and re-shape the MM BM immune niche. As such, novel immunotherapeutic approaches
have been developed over the past years improving MM patients’ outcome. However,
this remains an incurable hematological cancer and the search for the best combination
treatment continues.
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